Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

v3.22.2
Subsequent Events
6 Months Ended
Jun. 30, 2022
Subsequent Events  
Subsequent Events

Note 10 – Subsequent Events

Closing of Amended Credit Facility

On August 1, 2022, the Company entered into an amendment to the Credit Facility (the “Amendment”), that, among other things:

Added a new $150 million delayed-draw term loan, which matures on February 1, 2028 (the “New Term Loan”);

Extended the maturity date of the Revolver from May 2025 to August 2026; and

Transitioned all LIBOR-based loans under the Credit Facility to SOFR-based loans.

Loans based on LIBOR-based interest rates were transitioned to a SOFR-based interest rate equal to term SOFR plus a related spread adjustment of 10 basis points and a borrowing spread based on the current pricing grid in the Credit Facility. The interest rate on the New Term Loan is also equal to term SOFR plus a related spread adjustment of 10 basis points and a borrowing spread based on the current pricing grid in the Credit Facility. The Company may be entitled to a temporary reduction in the interest rate of two basis points provided it meets certain to be agreed upon sustainability goals. The accordion feature contained in the Credit Facility remains unchanged at $500 million.

In addition, on August 2, 2022, the Company entered into $150 million of forward starting interest rate swaps that commence in October 2022 and mature in January 2028 that will fix the SOFR component on the New Term Loan through January 2028 at 2.54%.

Completed Disposition of a Property

In July 2022, the Company sold a medical office building located in Germantown, Tennessee receiving gross proceeds of $17.9 million, resulting in an estimated gain of $6.8 million. As of June 30, 2022, the transaction did not meet the criteria to be classified as held for sale.